Haisco Pharmaceutical Hits Day Low of CNY 65.60 Amid Price Pressure

Haisco Pharmaceutical Group Co., Ltd. experienced a notable decline today, with the stock dropping by 3.94% as it reached an intraday low of CNY 65.60. This performance contrasts with the China Shanghai Composite, which saw a slight increase of 0.04% on the same day. Over the past week, Haisco's stock has decreased by 4.08%, and its monthly performance reflects a decline of 6.99%. Despite these short-term fluctuations, Haisco has demonstrated strong long-term growth, with a remarkable 214.96% increase over the past three years and a 29.68% rise year-to-date. The company reported a significant net profit growth of 1089.85% in its latest results, showcasing its operational strength. Key financial metrics indicate that Haisco maintains a solid return on equity of 15.84% and a high operating cash flow of CNY 1,126.55 million. The stock's current valuation reflects a price-to-book ratio of 7.75, indicating a premium valuation in the market. Overall, Haisco Pharmaceutical Group continues to be a significant player in the pharmaceuticals and biotechnology sector.